The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | TAISHAN-302: tambotatug pelitecan versus topotecan in relapsed SCLC
Anne Chiang, MD, PhD, Yale University School of Medicine, New Haven, CT, presents results from Phase III TAISHAN-302 trial (NCT06612151) of tambotatug pelitecan (Tam-Peli), a novel anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed small cell lung cancer (SCLC). Tam-Peli demonstrated statistically significant and clinically meaningful improvements in overall survival, progression-free survival, and objective response rate compared with topotecan, with a manageable safety profile, supporting its potential as a new standard-of-care second-line treatment option for relapsed SCLC. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
